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A b s t r a c t  
A chitosan molecule form self-assembled nanoparticles that can encapsulate a quantity of drugs and 
deliver them to a specific site. Chemical attachment of drug to chitosan throughout the functional 
linker has possibility to produce useful prodrugs, exhibiting biological activity at target site. In vivo 
residence time of the dosage form in the gastrointestinal tract and bioavailability of various drugs 
increases by mucoadhesive and absorption enhancement properties of chitosan. Antitumour activity 
of doxorubicin(DOX)-incorporated nanoparticles in vitro on DOX- resistant C6 glioma cells. 
Nanoparticles showed increased cytotoxicity compared to DOX alone. These results suggest that 
doxorubicin (DOX) was unable to penetrate into cells and did not effectively inhibit cell proliferation. 
In contrast, nanoparticles can penetrate into cells and effectively inhibit cell proliferation. 
There are 3 batches of drug loaded nanospheres in which 2.5mg,5mg and 10mg of DOX were 
loaded into nanospheres where the concentration of chitosan is 1%w/v. Anticancer drugs without 
targeting a specific site cause side effects. The objective of this research is to reduce side effects. 
HPLC device was used to quantitatively analyze amount of doxorubicin loaded in nanospheres. The 
result had showed concentration of anticancer drug loaded in nanospheres is directly proportional to 
the drug payload capacity until saturation point. The in vitro drug release studies was carried out for 
48 hours to obtain a more precise result by carrying out this studies in a medium resembling our 
body environment such as pH7.4, 37ÀC with analytical grade water for this studies. 
In vitro release of doxorubicin is of zero order kinetic. This shows that release is independent of the 
concentration of drug loaded in the nanospheres. Besides that, the graphs also show a sustained 
release manner, indicating these nanospheres formulation are suitable for targeting drug delivery 
system and for efficient treatment of cancerous cells. 
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Introduction 
Chemically, doxorubicin hydrochloride is (8S,10S)-10-[(3-amino-
2,3,6-trideoxyđ- L-lyxo-hexopyranosyl)oxy]-8-glycolyl-7,8,9,10-
tetrahydro-6,8,11-trihydroxy-1-methoxy5,12- naphthacenedione.  
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from 
cultures of Streptomyces peucetius var. caesius. Doxorubicin 
consists of a naphthacenequinone nucleus linked through a 
glycosidic bond at a ring atom 7 to an amino sugar, daunosamine. 
The anthracycline ring is lipophilic, but the saturated end of the ring 
system contains abundant hydroxyl groups adjacent to the amino 
sugar, producing a hydrophilic center. Thus, the molecule is 
amphoteric which contains acidic functions in the ring phenolic 
groups and a basic function in the sugar amino group. It binds to 
the cell membrane as well as plasma protein. Usually, it is supplied 
in the hydrochloride form as a sterile red-orange lyophilized powder 
containing lactose and as a sterile parenteral, isotonic solution with 
sodium chloride for intravenous use only. [1] 
 Several mechanisms have been proposed to explain DOX 
antitumor activity. There are 2 major mechanisms: the intercalation 
into DNA, leading to inhibition of the DNA synthesis or poisoning of 
topoisomerase II (TOP2A); and generation of free radicals, leading 
to DNA and cell membrane damage. [2] 
Targeted drug delivery is a form of delivery system where the drug 
is selectively targeted and delivered only to its site of action or 
absorption. The goal of a targeted drug delivery system is to 
concentrate the medication in the tissues of interest while reducing 
the relative concentration of the medication in the remaining 
tissues. This improves efficacy of the treatment while reducing side 
effects. [3] 
The use of nanotechnology in drug delivery and imaging in vivo is a 
rapidly expanding field. Present nanoscale systems available 
including liposomes, micelles, emulsions, nanoparticulates, and 
dendrimer nanocomposites. [4] 
Nanoparticles are sub-nanosized colloidal structures composed of 
synthetic or semi synthetic polymers. The major goals in designing 
nanoparticles as a delivery system are to control particle size, 
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surface properties and release of pharmacologically active agents 
in order to achieve the site-specific action of the drug at the 
therapeutically optimal rate and dose regimen.[5] 
The primary goals of nanoparticles in drug delivery include more 
specific drug targeting and delivery,reduction in toxicity while 
maintaining therapeutic effects,greater safety and biocompatibility, 
and faster development of new safe medicines.[6] 
Riddhi Dave et al [7] have prepared and evaluated chitosan 
nanoparticles containing doxorubicin by w/o emulsion method. 
They have prepared the nanoparticles using liquid paraffin 5%w/v 
and span 20. SEM indicated spherical structure of nanoparticle 
without agglomeration. In vitro drug release study suggests sustain 
drug release for longer period of time. The synthesized 
nanoparticles having diameter of 210nm are characterized by 
entrapment efficiency of 50-54%. Komal Patel et al [8] have 
prepared doxorubicin loaded Chitosan nanoparticles by ionic 
gelation method (IGM). An isocratic high-pressure liquid 
chromatography (HPLC) method was developed to quantify 
Doxorubicin Hydrochloride in rats plasma,vital organs. The 
Nanoparticles prepared by IGM show significantly increased the 
half life (T1/2) and mean residence time (MRT) of Doxorubicin in 
blood. [9] 
Materials and Methods 
Materials 
Doxorubicin was purchased from SunPharma India. Chitosan 
(150cps) was obtained from Central Marine Fisheries Research 
Institute Cochin, India. Sodium chloride was purchased from 
Unilab. 3% Glacial Acetic Acid , Toluene and Span 80 were 
purchased from Quicklab Sdn. Bhd. 25% aqueous Glutaraldehyde 
solution was supplied from Plant Succeed. Linseed oil was from 
Medina Jaya Sdn. Bhd. Acetone was purchased from Merck.  
Preparation of 1.0% w/v of 150cps Chitosan Gel  
150cps Chitosan and sodium chloride were dissolved in 3% glacial 
acetic acid and stirred with slight warming. Then, the solution was 
kept overnight for air drying under room temperature to obtain a 
clear gel of 1.0% w/v of 150cps chitosan. 
Preparation of Glutaraldehyde Saturated Toluene (GST) 
Glutaraldehyde and 7mL Toluene were mixed well for 30 minutes 
and then it was shaken vigorously. The solution was left overnight 
for saturation and separation. 
Preparation of Nanospheres without Drug Incorporation  
The 1%w/v chitosan gel was added with acetone dropwise with 
stirring. Polymer gel was added dropwise into linseed oil and 
allowed to emulsify under magnetic stirring at room temperature for 
one hour. Polymer was precipitated to the evaporation of acetone 
with subsequent formation of smaller spheres suspended in the oil 
phase. GST with Span 80 was added dropwise to the emulsion and 
it was continued stirring for 4 hours. The emulsion was centrifuged 
at 4800rpm for 20 minutes. The supernatant was discarded and 
fresh toluene was added and centrifuged at 4800rpm for 
20minutes. The centrifugation was repeated for 5 times. Acetone 
was added, mixed well and centrifuged at 4800rpm for 10minutes 
and repeated for 2 times. The content was dried in the incubator in 
glass petri plate. Powders were observed under 40X microscope. 
Preparation of Drug Loaded Nanospheres with 1.0% 
w/v 150cps Chitosan 
Three batches of 1.0% w/v of 150cps chitosan gel were prepared 
with different concentration of doxorubicin, which are 2.5mg, 5.0mg 
and 10.0mg. The emulsions were stirred stirrer for 1 hour then kept 
on standing for another 1 hour. 
Preparation of Doxorubicin-loaded nanospheres 
For the preparation of Doxorubicin-loaded nanospheres, firstly, 
acetone was added dropwise into beakers containing 1%w/v of 
150cps chitosan gel prepared with different doxorubicin 
concentrations in the ratio of 1:1. Then the polymer gel was added 
in dropwise into linseed oil and was allowed to emulsify under 
magnetic stirring. Polymer was precipitated to the evaporation of 
acetone with subsequent formation of smaller spheres suspended 
in the oil phase. GST layer was separated and the Toluene layer 
which had prepared was mixed with Span 80. GST with Span 80 
was added dropwise to the emulsion and it was continued stirring 
under magnetic stirrer. The emulsions in each beaker were 
centrifuged at 4800rpm and the upper oily supernatant was 
discarded. 
Toluene was added into each tube and shaken vigorously. The 
tubes were centrifuged at 4800rpm and the supernatant was 
discarded. This step was repeated a few times and after that, 
acetone was added, mixed well and centrifuged at 4800rpm. After 
centrifugation, acetone was added into each test tube and the 
mixture was mixed well. Upon drying, brown coloured and free 
flowing of fine powder was obtained. Powders were observed 
under 40X microscope (Figure 1 & 2). 
Figure 1: Chitosan Nanospheres under Microscope 40X 
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Figure 2: Doxorubicin-Chitosan Nanospheres under Microscope 
40X 
 
 
Preparation of calibration curve 
For the preparation of calibration curve, 1mg/ml of Doxorubicin 
stock solution was prepared. Then the stock solution was used to 
prepare Doxorubicin concentrations of 100øg/ml, 75øg/ml, 50øg/ml, 
25øg/ml, 12.5øg/ml and 6.25øg/ml by using serial dilution with 
deionized water. Standard solution was analyzed using HPLC and 
standard curve was plotted by taking the peak area at y-axis a 
concentration (øg/ml) at x-axis (Figure 3, Table 1). 
Optimization Method of HPLC Analysis of Doxorubicin 
Chromatographic separation was performed on a Shimadzu liquid 
chromatographic system equipped with a LC-10AT-vp solvent 
delivery system (pump),
Figure 3: Calibration Curve of Standard Doxorubicin HCl 
 
 
 
Table 1: The data for the preparation of calibration curve 
Concentration (μg/mL) Peak Area 
0.00 0 
6.25 293253 
12.5 603127 
25.0 1196055 
50.0 2392110 
75.0 3568164 
100.0 4904219 
SPD M 10AVP photo diode array detector, Rheodyne 7725i 
injector with 50 μl loop volume. Class-VP 6.01 data station was 
applied for data collecting and processing (Shimadzu, Japan).A 
Phenomenex Gemini C column (250 mmx 4.6 mm i.d., 5μ) was 
used for the separation, mobile phase of a mixture of acetonitrile 
(pH2.8) and 0.5% triethylamine (pH 3.5 adjusted with ortho 
phosphoric acid); (30:70 v/v) was delivered at a flow rate of 1.0 
ml/min with detection at 480 nm. The mobile phase was filtered 
through a 0.2μ membrane filter and degassed. The injection 
volume was 50 μl and the analysis was performed at ambient 
temperature (Figure. 4). 
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Figure 4: Typical Chromatogram of Doxorubicin HCl Standard 
 
Estimation of amount of drug incorporated 
Estimation of amount of drug incorporated can be done by 
digesting 10mg Doxorubicin drug filled nanospheres (Batch A,B,C) 
in 1:1 ratio of 0.1N Hydrochloric acid and ethanol. The sample 
collected was centrifuged at 5300rpm for 20 minutes. After 
centrifugation, solution was analysed for the amount of the drug 
present using HPLC at 480nm with the help of standard curve 
prepared previously (Figure 5, Table 2). 
 
Figure 5: Typical Chromatogram of Doxorubicin HCl Loaded Nanospheres 
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Table 2: Data for percentage drug loading in each batch of nanospheres 
Sample Total Weight 
(mg) 
Peak Area Concentration 
(μg/mL) 
Practical 
Loading (mg) 
Theoretical 
Loading (mg) 
Percentage Drug 
Loading (%) 
A 129.0 258645 5.6423 0.05642 0.1938 29.11 
B 149.9 482216 10.2407 0.1024 0.3336 30.70 
C 183.9 864419 18.1017 0.1810 0.5438 33.28 
 
 
In-vitro Drug Release Studies 
2.5mg/ml, 5mg/ml, 10mg/ml (Batch A,B,C) of drug loaded 
nanospheres were taken and 100ml of deionized water (pH7-7.4) 
was added into each of the conical flask. The flasks were kept in 
an incubator shaker at 37⁰C μ 0.5 ⁰C using 150 revolution/min for 
a span of 48 hours. 2ml of releasing solution was removed as 
samples at various time intervals and 1ml of releasing solution 
taken was then replaced with 2ml of deionized water immediately. 
The 2ml of releasing solution collected was passed through 0.45 
øm nylon membrane filter to be filtered. Drug content was 
estimated spectrophotometrically using HPLC at 480nm (Table 3).  
 
Table 3: In-vitro percentage release of doxorubicin from three batches of nanospheres (Sample A) 
Time interval 
(hours) 
Peak area Concentration (øg/ml) 
Amount of drug 
released (mg) 
Label 
Claim(mg) 
Percentage drug 
released (%) 
0 0 0 0 0.1411 0.00 
1 23534 0.8067 0.0807 0.1411 57.17 
2 24890 0.8346 0.0835 0.1411 59.15 
3 25013 0.8371 0.0837 0.1411 59.33 
4 25780 0.8529 0.0853 0.1411 60.44 
5 26580 0.8693 0.0869 0.1411 61.61 
6 27188 0.8818 0.0882 0.1411 62.50 
7 29275 0.9247 0.0925 0.1411 65.54 
8 29859 0.9368 0.0937 0.1411 66.39 
24 30179 0.9433 0.0943 0.1411 66.86 
28 41785 1.1820 0.1182 0.1411 83.77 
32 41955 1.1855 0.1186 0.1411 84.02 
48 42410 1.1949 0.1195 0.1411 84.68 
 
SEM Analysis 
SEM is a powerful method for visualizing the structure of 
nanospheres (Figures 6 and 7). Recently, we were able to show 
that this special preparation technique can be successfully used for 
the detection of nanospheres. 
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 Figure:6 SEM micrograph of the nanosphere 
 
 
  
Figure:7 SEM micrograph of the nanosphere
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Results and Discussion 
Chitosan is a modified natural carbohydrate polymer which is 
soluble in most organic acidic solutions at pH less than 6.5 
including formic, acetic, tartaric, and citric acid. By simple covalent 
modifications of the polymer, its physicochemical properties can be 
changed and can be made suitable for drug delivery purpose. Ionic 
interactions between positively charged amino groups in chitosan 
and the negatively charged mucus gel layer make it mucoadhesive. 
The favourable properties like biocompatibility, biodegradability, pH 
sensitiveness, and mucoadhesiveness have enabled chitosan to 
be chosen to be used as a polymer for nanoparticles. 
The major goals in designing nanoparticles as a delivery system 
are to control particle size, surface properties and release of 
pharmacologically active agents in order to achieve the site-
specific action of the drug at the therapeutically optimal rate and 
dose regimen. Nanospheres were prepared by modified 
spontaneous emulsification method which is water in oil emulsion 
type. First, chitosan was dissolved in glacial acetic acid to form an 
aqueous phase. After incorporating the drug into the system, 
linseed oil was added together with acetone into chitosan gel with 
drug mixture. It was allowed to emulsify under magnetic stirring.  
Prepared GST with span 80 was added into the mixture and it was 
allowed to precipitate by the evaporation of acetone to form 
nanospheres. Toluene was then used to remove remaining oil 
substance in the emulsion. Then acetone was used to remove the 
toluene and to dry the resulting substance to prevent aggregation.  
Some modifications were done in improving the formulation of 
nanospheres. 150cps chitosan was found to be better in the 
production of uniform and higher amount of nanospheres 
compared to 27 cps chitosan. 14mL glutaraldehyde instead of 7mL 
glutaraldehyde was used to form GST due to stronger cross linking 
and hardening of spherical particles. For better dispersion and less 
clumping of nanospheres, Span 80 in liquid form was utilized. In 
addition, the ingredients were added dropwise to ensure uniform 
mixing and further reduce the occurrence of aggregation. 
Frequency of washing with toluene was increased to maximize the 
removal of oil content before the washing of nanospheres with 
acetone. In the estimation of amount of drug incorporated, the 
three batches of drug filled nanospheres were digested with the 
ratio of 1:1 of 0.1N Hydrochloric acid and ethanol.  
Three batches of nanospheres were prepared with the 
incorporation of 2.5mg(batch A), 5.0mg(batch B) and 10.0mg(batch 
C) of doxorubicin respectively. The concentration of drug 
incorporated was found to be 5.6423øg/mL, 10.2407øg/mL and 
18.1017øg/mL for batch A, batch B and C respectively. Results 
show the drug loading capacity of 2.5mg batch was 29.11%, 5.0mg 
batch was 30.70% and 10mg batch was 33.28%. Based on the 
data in Table 3, when drug to polymer ratio was increased, the 
drug payload capacity was also increased. 
In the in-vitro drug release study, deionised water with pH 7.4 was 
used at the temperature 37ÀC which is similar to the internal 
environment of the body for the maximum drug release. From the 
figures 6, 7, and 8, it was observed that the in-vitro release of 
doxorubicin is zero order kinetics, which means that the release is 
independent of the concentration of the drug loaded in the 
nanospheres. It also showed a biphasic repsonse, whereby there 
was an initial burst release of drug from the nanospheres, followed 
by a plateau where the release of drug became constant and 
independent of drug concentration. 50% drug release in 2.5mg 
batch is at the 1st hour, whereas for the 5.0mg batch is at the 4th 
hour. The 50% drug release in 10mg batch on the other hand is at 
the 8th hour. Hence, it shows that the rate of drug release is 
inversely proportional to the drug loading. The highly drug-loaded 
nanospheres in 10mg batch shows slower onset action and 
prolonged release profile. This advantage enables the decrease in 
dosing frequency of anticancer drug. At the same time, there will 
be decrease in the occurrence of side effects. The release pattern 
and percentage drug release shown by the nanospheres was 
found satisfactory. However, the further optimization of the 
analytical method is required and the in vitro release study it is 
worthwhile to study the drug release in various mediums in order to 
thoroughly understand the behavior of drug release. be studied 
thoroughly to understand the behaviour of the drug release. 
Conclusion 
Three batches of nanospheres were formulated with varying 
amount of drug payload. The drug to polymer ratio is proportional 
to the drug payload capacity. It was shown that through our in-vitro 
release studies that the greater the amount of drug incorporated 
will result in slower rate of drug release. This indicates a sustained 
release of the drug from the nanospheres with higher drug pay 
load.  
Initially, the graphs obtained from in vitro drug release studies 
shown a biphasic release, that is an initial burst release, followed 
by a plateau where the release of drug is constant and 
independent of drug concentration. This feature is one of the 
objectives of drug targeting delivery system. The small size of 
nanospheres enables rapid absorption in our circulation system 
and will accumulate especially in cancerous tissues with reduced 
doxorubicin systemic toxicity. This also facilitates the targeting drug 
delivery system. 
This research has indeed achieved its main objective which is to 
provide the maximum therapeutic efficacy with the most reduced 
side effects. In a nut shell, there is a bright future for the 
development of doxorubicin-chitosan nanoparticles as one of the 
most efficient drug carrier for the treatment of cancer. 
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